Doptelet(avatrombopag)
Doptelet (avatrombopag) is a small molecule pharmaceutical. Avatrombopag was first approved as Doptelet on 2018-05-21. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. It is known to target thrombopoietin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Doptelet
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| doptelet | New Drug Application | 2024-07-30 |
| doptelet doptelet sprinkle | New Drug Application | 2025-08-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| thrombocytopenia | HP_0001873 | D013921 | D69.6 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AVATROMBOPAG MALEATE, DOPTELET, AKARX INC | |||
| 2026-06-26 | ODE-246 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Avatrombopag Maleate, Doptelet, Akarx Inc | |||
| 7638536 | 2027-07-28 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
62 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 1 | — | — | 1 | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Avatrombopag |
| INN | avatrombopag |
| Description | Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure. It was approved for medical use in the United States in May 2018, the European Union in June 2019, and Australia in January 2023.
|
| Classification | Small molecule |
| Drug class | thrombopoetin agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1 |
Identifiers
| PDB | — |
| CAS-ID | 570406-98-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103883 |
| ChEBI ID | — |
| PubChem CID | 9852519 |
| DrugBank | DB11995 |
| UNII ID | 3H8GSZ4SQL (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MPL
MPL
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 564 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,782 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use